 Neurocrine is acquiring beaten-down Diurnal Group for 57M, primarily to accelerate its ex-U.S. business development. Diurnal has a pipeline of hormone-based therapeutics, including Efmody commercialized in Europe, but the pipeline is likely secondary to the clinicalcommercial infrastructure Diurnal offers. 